Last updated: April 2026. We review this article quarterly.

Naltrexone for Weight Loss: What the Evidence Actually Shows

You've probably seen it mentioned on Reddit, heard a podcast host reference it, or stumbled across a telehealth clinic advertising it for weight loss. Naltrexone keeps coming up in weight loss conversations, and for good reason. But here's the first thing your provider should have told you: naltrexone by itself is not FDA-approved for weight loss. That's a critical distinction, and most websites bury it.

What IS FDA-approved is Contrave, a fixed-dose combination of naltrexone and bupropion. The drug that gets prescriptions approved by insurance is not naltrexone alone. Prescribing naltrexone solo for weight loss is off-label, which doesn't make it wrong, but it does mean the FDA hasn't formally evaluated that use.

This article covers both realities: what the clinical data says about naltrexone for weight loss (including the limited evidence for low dose naltrexone on its own), how the combination with bupropion actually works, and whether any of this makes sense for your situation.

Is Naltrexone FDA-Approved for Weight Loss?

Naltrexone alone is NOT FDA-approved for weight loss. It's approved for opioid use disorder (1984) and alcohol use disorder (1994), both at a 50 mg daily dose. Any prescription you get for naltrexone targeting weight loss is off-label use (Gudzune & Kushner, 2024).

The FDA-approved medication for weight loss in the naltrexone family is Contrave, which combines naltrexone 32 mg SR (sustained release) with bupropion 360 mg SR. These aren't interchangeable. Contrave went through four large Phase 3 clinical trials before the FDA approved it in 2014. Naltrexone alone has no comparable trial data for weight loss as a standalone medication.

This distinction matters when you're evaluating options. If someone is prescribing "naltrexone for weight loss" at 4.5 mg, 16 mg, or 50 mg without bupropion, they're working off-label with a thinner evidence base than Contrave's. That doesn't mean it can't work — off-label prescribing happens constantly in medicine and is often well-supported. But you should know where the formal approval lines are before you spend money or alter your expectations.

How Naltrexone Works in the Brain

Naltrexone is an opioid receptor antagonist. It blocks the mu-opioid receptors in your brain, which is how it helps with addiction: it prevents opioids from producing their rewarding effects, making relapse less appealing.

For weight loss, the theory is more interesting and more complicated. Your hypothalamus runs a feedback loop involving pro-opiomelanocortin (POMC) neurons, which regulate appetite and energy balance. Bupropion stimulates these POMC neurons, which should suppress appetite. But here's the wrinkle: when POMC neurons activate, they also release beta-endorphin, which feeds back and inhibits the very neurons that were just stimulated. It's a built-in brake.

Naltrexone, by blocking opioid receptors, disrupts this feedback brake. The result is that bupropion's appetite-suppressing effect can sustain longer than it would alone. This is the mechanism described in the foundational "rational design" paper (Greenway et al., 2009) that set the scientific basis for Contrave. A brain imaging study (Wang et al., 2013) later confirmed this: the combination attenuated hypothalamic activation in response to food cues while enhancing activity in brain regions involved in inhibitory control.

In isolation, when you take naltrexone without bupropion, you're theoretically removing that brake but you don't have the bupropion driving the POMC activation in the first place. Some researchers hypothesize that naltrexone alone could reduce reward-driven eating by blunting the opioid-mediated pleasure signals from food, particularly in people with strong food noise or emotional eating patterns.

The data on whether this works in practice, at any dose, is genuinely thin.

What Does the Evidence Say About Naltrexone Alone for Weight Loss?

This is where honest framing matters. The short answer: naltrexone alone for weight loss does not have strong clinical evidence. The clearest data comes from the 1980s, and it's not encouraging.

In a double-blind, placebo-controlled 8-week trial (Atkinson et al., 1985), 60 obese patients received either 0, 50, or 100 mg of naltrexone daily. Weight loss in the naltrexone groups was not significantly different from placebo overall. Women showed a modest significant loss of 1.7 kg compared to men who showed no benefit. A follow-up study (Malcolm et al., 1985) using 200 mg daily in 41 subjects found no significant difference between naltrexone and placebo after 10 weeks.

A high-dose trial (Mitchell et al., 1987) used 300 mg daily (six times the standard addiction dose) in obese men with dietary counseling. The naltrexone group did not lose more weight. Worse, the drug was associated with hepatotoxicity at that dose: liver enzyme elevations appeared in multiple subjects. This ruled out high-dose naltrexone as a weight loss strategy.

So what about low dose naltrexone specifically? LDN (typically 1.5-4.5 mg daily, far below the addiction dose) operates through a different proposed mechanism: a brief, partial blockade of opioid receptors that theoretically triggers a rebound increase in endorphin and enkephalin production. Some researchers believe this immune-modulating and anti-inflammatory effect could influence metabolic function. But there are no completed randomized controlled trials specifically using LDN for weight loss in otherwise healthy adults. The clinical trial registry shows LDN being studied for fatigue, Crohn's disease, multiple sclerosis, and painful neuropathy — not obesity as a primary indication.

The community experiences on Reddit and in LDN forums are mixed. Some people report appetite reduction and modest weight loss. Others report no effect. Without controlled trial data, it's impossible to separate placebo from pharmacology, and individual variation in response is impossible to predict.

The Combination That Actually Has Evidence: Naltrexone/Bupropion (Contrave)

When you add bupropion to naltrexone, the evidence changes substantially. This is where the Phase 3 trial data lives.

The COR-BMOD trial (Wadden et al., 2011) enrolled 793 participants with a mean BMI of 36.5 and ran for 56 weeks. Participants received either placebo plus intensive behavioral modification or naltrexone 32 mg SR plus bupropion 360 mg SR plus the same behavioral program. At week 56, the combination therapy group lost 9.3% of body weight versus 5.1% in the placebo group (p < 0.001). In the group that completed the full trial, weight loss was 11.5% for the NB combination versus 7.3% for placebo. If you start at 200 pounds, 9.3% is about 18.6 pounds over a year. Not as dramatic as GLP-1 medications, but meaningfully more than placebo with behavioral support.

The COR-Diabetes trial (Hollander et al., 2013) tested the same combination in 505 overweight and obese patients with Type 2 diabetes. Weight loss was -5.0% for naltrexone/bupropion versus -1.8% for placebo (p < 0.001). The HbA1c also dropped 0.6% versus 0.1% for placebo, and significantly more patients achieved HbA1c below 7%. The blood sugar improvement was a secondary but meaningful finding. Side effects were significant: nausea hit 42.3% of the treatment group versus 7.1% for placebo.

A 2009 dose-finding trial (Greenway et al., 2009) compared different naltrexone doses with bupropion and found that placebo-subtracted weight loss at 24 weeks was approximately 4.6-4.7% for the NB16 and NB32 combinations. The combination beat monotherapy with either drug alone.

How does this stack up against other anti-obesity medications? A 2021 meta-analysis (Tak & Lee, 2021) compared placebo-subtracted weight reduction across FDA-approved options over at least 12 months: phentermine/topiramate led at 6.8%, liraglutide at 5.4%, naltrexone/bupropion at 4.0%, and orlistat at 2.9%. That puts Contrave solidly in the middle of the pack. GLP-1 medications (semaglutide, tirzepatide) weren't yet in that analysis but significantly outperform all of the older agents (Chakhtoura et al., 2023).

For a broader picture of how GLP-1 medications compare to each other and to older agents like Contrave, that guide breaks down the head-to-head data.

Low Dose Naltrexone (LDN): What Is It, and Who Uses It?

Low dose naltrexone refers to doses typically between 1.5 mg and 4.5 mg per day, 10-30 times lower than the addiction-treatment dose of 50 mg. At 4.5 mg, the most commonly used LDN dose, the opioid receptor blockade is brief (a few hours) rather than sustained. The theoretical mechanism is that this transient blockade causes a compensatory upregulation of endorphin production.

LDN is prescribed off-label for conditions including fibromyalgia, Crohn's disease, multiple sclerosis-related fatigue, and chronic pain. It appears in a recruiting Phase 2/3 trial (NCT07092618, AgelessRx) as one option for maintaining weight after stopping GLP-1 medications. That's a meaningful research signal: there's enough clinical interest to test LDN in a GLP-1 transition context, even without strong standalone weight loss data.

For weight management specifically, the conversation around LDN focuses mainly on people with strong food addiction patterns, emotional eating, or reward-driven overeating. The thinking is that if opioid signaling drives the pleasure you get from food, blunting that signal might reduce the compulsion. This is biologically plausible. It's not yet clinically proven for weight loss.

The typical LDN starting dose is 1.5 mg taken at bedtime, titrated up over weeks to 4.5 mg. Some providers go as high as 8 mg for weight-adjacent off-label use, though this is further from the LDN protocol and closer to standard naltrexone territory.

One consideration if you're currently on opioid medications: naltrexone at any dose will block their effects. You cannot use LDN alongside opioid pain medications, methadone, or buprenorphine. This is a hard contraindication.

Naltrexone vs Contrave: What's the Difference?

People often search "naltrexone for weight loss" when they actually want information about Contrave. These are not the same thing, and the distinction matters for effectiveness, cost, and insurance coverage.

Feature	Naltrexone (standalone, off-label)	Contrave (naltrexone/bupropion, FDA-approved)
FDA approved for weight loss	No	Yes (2014)
Typical dose range	4.5 mg (LDN) to 50 mg	32 mg naltrexone + 360 mg bupropion SR
Clinical trial data (weight loss)	Very limited (1980s only)	4 Phase 3 RCTs, 3,500+ participants
Insurance coverage	Rarely covered for weight loss	Sometimes covered; coverage varies
Monthly cost	$10-50 (generic, compounded LDN)	$100-400 without insurance
Mechanism	Opioid receptor blockade alone	Opioid receptor blockade + POMC stimulation

Contrave has a black box warning for increased risk of suicidal thoughts, a class-wide warning for bupropion (the antidepressant component). If you have a history of seizures, eating disorders, or are taking MAOIs, Contrave is contraindicated.

For a detailed look at Contrave specifically, including its full side effect profile and who it's best suited for, see the complete Contrave guide.

Who Might Benefit From Naltrexone for Weight Loss?

This is where physician judgment and individual assessment matter most. Given the evidence as it stands, naltrexone alone for weight loss makes the most theoretical sense in specific situations.

You're a candidate for LDN discussion if you have strong food noise: constant preoccupation with food, reward-driven eating, or a history of using food the way some people use alcohol, for stress relief and emotional regulation. If the opioid reward system is driving your eating patterns, blunting it could reduce that signal. This is the main rationale providers use when prescribing off-label LDN for weight management.

You might also be a reasonable candidate if you're looking for a bridge strategy while transitioning off a GLP-1 medication. The AgelessRx trial examining LDN for GLP-1 maintenance (NCT07092618) reflects real clinical uncertainty about how to preserve weight loss after stopping semaglutide or tirzepatide.

LDN is not a good fit if you have liver disease (naltrexone is metabolized by the liver and carries hepatotoxicity risk at high doses), if you're on opioid medications, or if you're expecting GLP-1-level weight loss. The honest expectation for LDN is modest at best, largely based on case reports and community experience rather than controlled trials.

Contrave makes more sense if you need FDA-approved treatment with insurance coverage potential, have issues with both appetite control and the mood/reward dimension of eating, or have Type 2 diabetes (the Hollander 2013 data showed meaningful HbA1c improvement alongside weight loss). If you've been deterred from GLP-1s by side effects, the Ozempic side effects guide explains what most people actually experience and how to manage nausea in the first weeks.

A broader review (Chakhtoura et al., 2023) puts it plainly: naltrexone/bupropion is one of five medications approved for non-syndromic obesity, with efficacy below the newer GLP-1 agents but meaningful for the right patient profile. The right patient selection is the key variable. A 2024 JAMA review (Gudzune & Kushner, 2024) echoes this, noting that centrally acting drugs like naltrexone/bupropion cause constipation in roughly 20% of patients, though nausea varies considerably by medication.

If you're trying to navigate this decision, it's also worth reading about how a registered dietitian supports weight loss — these practitioners often work alongside pharmacotherapy protocols to address behavioral eating patterns that medication alone doesn't fix.

Safety and Side Effects

At the standard 50 mg naltrexone dose, the most common reported adverse events in FDA FAERS data for weight-loss-related use include fatigue (14 reports), headache (10), pain (10), joint pain (8), dizziness (7), and depression (6). All 65 adverse event reports in the FAERS database were classified as serious reports. This doesn't mean 65 serious events from weight loss prescriptions specifically, since FAERS includes all-cause reporting, but it does reflect the drug's real adverse event profile.

At LDN doses (1.5-4.5 mg), side effects are generally mild. Vivid dreams, sleep disturbances in the first few weeks, and mild nausea are the most commonly reported in the LDN community. These typically resolve within 2-4 weeks as the body adjusts to the intermittent opioid blockade.

Liver toxicity is a real concern at high doses. The Mitchell 1987 trial showed hepatotoxicity at 300 mg. At therapeutic doses for addiction (50 mg) and LDN doses (4.5 mg), hepatotoxicity is rare but liver function should be checked in people with pre-existing liver conditions.

For Contrave specifically, the combination with bupropion adds side effects from the antidepressant: nausea (42% in the Hollander trial), constipation, dry mouth, and insomnia. The black box warning on bupropion about suicidality means patients with depression or psychiatric history need careful monitoring.

Cost, Coverage, and Access

Naltrexone alone (off-label for weight loss): Generic naltrexone 50 mg tablets cost $10-50/month through most pharmacies, sometimes less with GoodRx. If a provider prescribes the lower 4.5 mg LDN dose, the drug needs to be compounded (since standard tablets come in 50 mg). Compounded LDN typically runs $30-80/month from a compounding pharmacy. Most insurance plans won't cover naltrexone when prescribed off-label for weight loss.

Contrave: Without insurance, Contrave's list price runs $400-500/month or more. With insurance coverage (which is inconsistent and often requires prior authorization), costs can drop to $30-100/month copay. The manufacturer offers a savings card program that can reduce out-of-pocket costs for commercially insured patients to as low as $99/month. Medicare and Medicaid coverage is limited.

The cost gap between off-label naltrexone and GLP-1 medications like semaglutide isn't as large as most people assume. Compounded LDN at $30-80/month is significantly cheaper than brand-name GLP-1s, but compounded semaglutide is now available at $200-350/month at many telehealth providers. If the efficacy ceiling for LDN is modest and uncertain, the cost calculus matters.

At HEXIS, if you're considering naltrexone or Contrave as part of your weight management approach, we start with labs. Understanding your full metabolic panel, thyroid function, and liver baseline before starting either medication isn't optional — it's how you prescribe safely. Your HEXIS provider will also look at whether the behavioral eating patterns that might respond to an opioid antagonist are actually present in your history, or whether a different approach fits better.

Telehealth is available nationwide, and Great Falls, MT patients can see providers in clinic.

Frequently Asked Questions

What's considered low dose naltrexone, and is it the same as what's used for weight loss?

Low dose naltrexone (LDN) refers to doses between 1.5 mg and 4.5 mg daily, taken at bedtime. Standard naltrexone for addiction is 50 mg. LDN at 4.5 mg is roughly 11 times lower. When providers prescribe naltrexone off-label for weight loss, they're usually prescribing in this LDN range. Some use the full 50 mg dose, particularly when prescribing it informally as a Contrave-adjacent treatment. The dose determines the mechanism: LDN works through transient opioid blockade and endorphin rebound; 50 mg works through sustained blockade. Neither has strong weight-loss-specific RCT data without bupropion.

Does naltrexone alone cause meaningful weight loss?

The controlled trial data on naltrexone alone for weight loss is discouraging. 1980s studies using 50-200 mg found no significant weight loss compared to placebo overall, with one exception: women showed a modest 1.7 kg benefit in the Atkinson 1985 study. Community reports of LDN-related appetite reduction exist but can't be separated from placebo effects without controlled trials. Honest answer: meaningful, reproducible weight loss from naltrexone alone has not been demonstrated in controlled research.

How does LDN work differently from Contrave for weight loss?

Contrave works through dual mechanisms: bupropion activates POMC neurons in the hypothalamus (appetite suppression), while naltrexone blocks the opioid feedback that would normally shut that activation down. The combination sustains appetite suppression longer than either drug alone. LDN on its own doesn't have the bupropion component driving POMC activation. LDN's proposed weight-relevant mechanism is more indirect: transient opioid blockade theoretically reduces food reward signaling and compulsive eating. Contrave has four large Phase 3 trials supporting it. LDN for weight loss has essentially none.

Can naltrexone help if I have emotional eating or food addiction?

This is the most clinically plausible use case for off-label naltrexone. If your eating patterns are driven by opioid-mediated reward (the pleasure and relief you get from food), blocking those receptors could reduce the compulsion. Some providers use LDN specifically for this profile. Whether it's effective for you specifically requires a clinical assessment of your eating patterns, not just your BMI. A provider who prescribes it without that conversation isn't doing the full evaluation.

What happens to naltrexone if I need opioid pain medication?

You cannot take any opioid medication while on naltrexone. It will block the opioid's effects completely, which can also precipitate withdrawal in opioid-dependent patients. This includes prescription opioids for pain, opioid-based anesthetics, and opioid cough medications. If you have surgery scheduled or anticipate needing opioid pain management, naltrexone must be stopped and cleared from your system first. This is a non-negotiable, serious drug interaction.

The Bottom Line

Naltrexone is an interesting drug with a well-understood mechanism and decades of safety data in addiction medicine. For weight loss specifically: naltrexone alone is off-label, and the controlled trial data on standalone use is genuinely thin. Low dose naltrexone (4.5 mg) is the version most discussed in the weight loss context, but there are no completed RCTs supporting it as a primary obesity treatment.

Contrave (naltrexone plus bupropion) has solid Phase 3 trial data, FDA approval, and a defined role in obesity pharmacotherapy, with about 4% more weight loss than placebo at one year. It's not the most potent option available today, but it has a dual mechanism that may be particularly relevant for patients with emotional eating, food addiction patterns, or depression-adjacent weight gain.

If you're thinking about naltrexone for weight loss, the decision needs to start with a clinical evaluation, not a prescription request. Understanding whether opioid reward pathways are actually a driver of your specific eating patterns, checking liver function, ruling out contraindications, and setting realistic expectations matters before anything else.

If you want to explore whether naltrexone for weight loss makes sense for you, schedule a consultation at HEXIS. Your provider will start with labs and a full evaluation, not a one-size-fits-all prescription.

---